Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanjin Fuyan is a Traditional Chinese Medicine (TCM) formulation developed by Guilin Sanjin Pharmaceutical for the treatment of chronic pelvic inflammatory disease (CPID). It is specifically indicated for patients presenting with damp-heat stasis syndrome. The formulation typically functions by clearing heat, removing dampness, and promoting blood circulation to resolve stasis, thereby alleviating the inflammation and pain associated with CPID. As a botanical/herbal product, its efficacy is attributed to the synergistic effects of its constituent plant extracts, which are processed into a tablet form for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanjin Fuyan.